Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Clostridium Infections | 19 | 2023 | 564 | 4.220 |
Why?
|
Bacterial Toxins | 6 | 2023 | 924 | 1.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 11 | 2022 | 5753 | 1.090 |
Why?
|
Antilymphocyte Serum | 1 | 2024 | 493 | 0.790 |
Why?
|
Cryptosporidiosis | 1 | 2021 | 52 | 0.730 |
Why?
|
Adenoviridae Infections | 1 | 2018 | 97 | 0.600 |
Why?
|
Hematologic Neoplasms | 2 | 2020 | 1927 | 0.570 |
Why?
|
Kidney Transplantation | 5 | 2024 | 4270 | 0.550 |
Why?
|
Immunomodulation | 1 | 2020 | 547 | 0.540 |
Why?
|
Infection Control | 2 | 2020 | 983 | 0.530 |
Why?
|
Cross Infection | 3 | 2020 | 1427 | 0.520 |
Why?
|
Sparganosis | 1 | 2015 | 4 | 0.500 |
Why?
|
Spirometra | 1 | 2015 | 4 | 0.500 |
Why?
|
Ehrlichiosis | 1 | 2014 | 28 | 0.470 |
Why?
|
Lymphoma, B-Cell | 1 | 2021 | 943 | 0.460 |
Why?
|
Anaplasma phagocytophilum | 1 | 2014 | 37 | 0.460 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 669 | 0.450 |
Why?
|
Feces | 5 | 2023 | 1504 | 0.430 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2018 | 365 | 0.430 |
Why?
|
Graft Survival | 1 | 2024 | 3890 | 0.420 |
Why?
|
Bacteremia | 2 | 2024 | 989 | 0.420 |
Why?
|
Bone Marrow Transplantation | 1 | 2020 | 2729 | 0.400 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2014 | 183 | 0.400 |
Why?
|
beta-Thalassemia | 1 | 2014 | 233 | 0.390 |
Why?
|
Breast Diseases | 1 | 2015 | 436 | 0.390 |
Why?
|
Vaccines | 1 | 2020 | 841 | 0.390 |
Why?
|
Enterotoxins | 3 | 2023 | 366 | 0.380 |
Why?
|
Psoas Abscess | 1 | 2011 | 11 | 0.380 |
Why?
|
Graft Rejection | 2 | 2024 | 4499 | 0.380 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2013 | 265 | 0.370 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1510 | 0.370 |
Why?
|
Respiratory Tract Infections | 1 | 2018 | 1008 | 0.350 |
Why?
|
Fetal Blood | 1 | 2017 | 1369 | 0.350 |
Why?
|
Diarrhea | 3 | 2023 | 1316 | 0.330 |
Why?
|
Erythrocyte Transfusion | 1 | 2014 | 568 | 0.330 |
Why?
|
Immunologic Factors | 1 | 2018 | 1587 | 0.320 |
Why?
|
Anti-Bacterial Agents | 12 | 2024 | 7478 | 0.280 |
Why?
|
Transplantation Conditioning | 2 | 2017 | 1635 | 0.280 |
Why?
|
Antiviral Agents | 2 | 2021 | 3050 | 0.280 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 705 | 0.230 |
Why?
|
Recurrence | 6 | 2022 | 8501 | 0.210 |
Why?
|
Antibodies, Bacterial | 2 | 2022 | 1476 | 0.210 |
Why?
|
Pneumocystis carinii | 1 | 2023 | 70 | 0.210 |
Why?
|
Ribotyping | 1 | 2022 | 35 | 0.210 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2022 | 142 | 0.210 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 2187 | 0.200 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2023 | 239 | 0.200 |
Why?
|
Staphylococcal Infections | 1 | 2011 | 1393 | 0.200 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2022 | 79 | 0.190 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2024 | 339 | 0.180 |
Why?
|
Toxemia | 1 | 2020 | 14 | 0.180 |
Why?
|
Mucormycosis | 2 | 2013 | 104 | 0.180 |
Why?
|
Retrospective Studies | 14 | 2024 | 81514 | 0.180 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 125 | 0.170 |
Why?
|
Norovirus | 1 | 2020 | 36 | 0.170 |
Why?
|
Laxatives | 1 | 2020 | 94 | 0.170 |
Why?
|
Bacterial Proteins | 3 | 2022 | 3837 | 0.160 |
Why?
|
Humans | 39 | 2024 | 765968 | 0.160 |
Why?
|
Treatment Outcome | 10 | 2024 | 65188 | 0.160 |
Why?
|
Antibodies, Neutralizing | 2 | 2021 | 2010 | 0.160 |
Why?
|
Immunoenzyme Techniques | 1 | 2022 | 1701 | 0.160 |
Why?
|
North America | 1 | 2022 | 1285 | 0.160 |
Why?
|
Organ Transplantation | 2 | 2023 | 1174 | 0.160 |
Why?
|
Gastroenteritis | 1 | 2020 | 229 | 0.150 |
Why?
|
HIV Infections | 1 | 2024 | 17533 | 0.140 |
Why?
|
Pancreas Transplantation | 1 | 2018 | 194 | 0.140 |
Why?
|
Middle Aged | 20 | 2024 | 223009 | 0.140 |
Why?
|
Respiratory Syncytial Viruses | 1 | 2018 | 168 | 0.140 |
Why?
|
Adult | 15 | 2024 | 223044 | 0.140 |
Why?
|
Interleukin-1beta | 1 | 2023 | 1028 | 0.140 |
Why?
|
Eye Diseases | 1 | 2022 | 659 | 0.140 |
Why?
|
Immunocompromised Host | 1 | 2021 | 866 | 0.130 |
Why?
|
Food Parasitology | 1 | 2015 | 6 | 0.130 |
Why?
|
Anura | 1 | 2015 | 79 | 0.120 |
Why?
|
Praziquantel | 1 | 2015 | 34 | 0.120 |
Why?
|
Female | 20 | 2024 | 396112 | 0.120 |
Why?
|
Antiparasitic Agents | 1 | 2015 | 41 | 0.120 |
Why?
|
Foodborne Diseases | 1 | 2015 | 41 | 0.120 |
Why?
|
Metronidazole | 1 | 2016 | 236 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2021 | 1555 | 0.120 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2014 | 13 | 0.120 |
Why?
|
Blood Safety | 1 | 2014 | 16 | 0.120 |
Why?
|
Exophiala | 1 | 2014 | 2 | 0.120 |
Why?
|
Virus Activation | 1 | 2017 | 323 | 0.120 |
Why?
|
Anti-Retroviral Agents | 1 | 2024 | 1787 | 0.110 |
Why?
|
Antibiotic Prophylaxis | 1 | 2019 | 644 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2022 | 1383 | 0.110 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2014 | 425 | 0.110 |
Why?
|
Food Contamination | 1 | 2015 | 194 | 0.110 |
Why?
|
Incidence | 6 | 2017 | 21480 | 0.110 |
Why?
|
Vancomycin | 1 | 2016 | 504 | 0.110 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2022 | 2203 | 0.110 |
Why?
|
Male | 18 | 2024 | 363698 | 0.100 |
Why?
|
Blood Donors | 1 | 2014 | 342 | 0.100 |
Why?
|
Communicable Diseases, Emerging | 1 | 2014 | 150 | 0.100 |
Why?
|
Rifampin | 1 | 2014 | 351 | 0.100 |
Why?
|
Cytomegalovirus | 1 | 2017 | 751 | 0.100 |
Why?
|
Opportunistic Infections | 2 | 2014 | 376 | 0.100 |
Why?
|
Risk Factors | 9 | 2024 | 74840 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1434 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2024 | 2495 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6309 | 0.090 |
Why?
|
Rhizopus | 1 | 2011 | 22 | 0.090 |
Why?
|
Carrier State | 1 | 2015 | 529 | 0.090 |
Why?
|
Length of Stay | 2 | 2018 | 6485 | 0.090 |
Why?
|
Fournier Gangrene | 1 | 2011 | 22 | 0.090 |
Why?
|
Immunosuppressive Agents | 1 | 2024 | 4209 | 0.090 |
Why?
|
Graft vs Host Disease | 2 | 2014 | 3078 | 0.090 |
Why?
|
Dermatomycoses | 1 | 2011 | 45 | 0.090 |
Why?
|
Aspergillosis | 1 | 2013 | 242 | 0.090 |
Why?
|
Penile Diseases | 1 | 2011 | 47 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2014 | 452 | 0.090 |
Why?
|
Baltimore | 1 | 2011 | 232 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8529 | 0.090 |
Why?
|
Cytomegalovirus Infections | 1 | 2017 | 836 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3211 | 0.080 |
Why?
|
Viral Load | 1 | 2018 | 3386 | 0.080 |
Why?
|
China | 1 | 2015 | 2385 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2535 | 0.080 |
Why?
|
Transplantation, Autologous | 1 | 2013 | 2120 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2021 | 59489 | 0.070 |
Why?
|
Immunoglobulin A | 2 | 2023 | 995 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6499 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2243 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2020 | 2780 | 0.060 |
Why?
|
Aged | 9 | 2023 | 171117 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2024 | 22223 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2018 | 5343 | 0.060 |
Why?
|
Patient Readmission | 1 | 2018 | 3286 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5891 | 0.060 |
Why?
|
Anti-Infective Agents | 1 | 2011 | 986 | 0.050 |
Why?
|
Cohort Studies | 4 | 2021 | 41649 | 0.050 |
Why?
|
Young Adult | 5 | 2021 | 59889 | 0.050 |
Why?
|
Antitoxins | 1 | 2023 | 75 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12509 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15880 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8626 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8875 | 0.050 |
Why?
|
Cytosine | 1 | 2021 | 213 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 9249 | 0.040 |
Why?
|
Caliciviridae Infections | 1 | 2020 | 28 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4528 | 0.040 |
Why?
|
Teaching Rounds | 1 | 2023 | 280 | 0.040 |
Why?
|
Quebec | 1 | 2017 | 140 | 0.030 |
Why?
|
Europe | 1 | 2023 | 3423 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2021 | 605 | 0.030 |
Why?
|
Comorbidity | 1 | 2011 | 10563 | 0.030 |
Why?
|
Mucositis | 1 | 2017 | 107 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2011 | 3646 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2014 | 26346 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2023 | 2132 | 0.030 |
Why?
|
Drug Resistance, Fungal | 1 | 2014 | 79 | 0.030 |
Why?
|
United States | 1 | 2022 | 72903 | 0.030 |
Why?
|
Child | 1 | 2022 | 80564 | 0.030 |
Why?
|
Time Factors | 2 | 2012 | 40065 | 0.030 |
Why?
|
Pregnancy | 1 | 2014 | 30260 | 0.030 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2014 | 238 | 0.020 |
Why?
|
Adolescent | 2 | 2017 | 88835 | 0.020 |
Why?
|
Medical Records | 1 | 2016 | 1409 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2017 | 1472 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1759 | 0.020 |
Why?
|
Colonoscopy | 1 | 2018 | 1406 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2014 | 769 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7562 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2017 | 4860 | 0.020 |
Why?
|
Colitis | 1 | 2016 | 1239 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9338 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2021 | 12437 | 0.020 |
Why?
|
Animals | 2 | 2017 | 168764 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2023 | 7425 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10261 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10383 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8041 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 13462 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13632 | 0.010 |
Why?
|
Concepts
(176)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(54)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_